PMID- 25222079
OWN - NLM
STAT- MEDLINE
DCOM- 20160216
LR  - 20191210
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 16
IP  - 7
DP  - 2015 Jul
TI  - Heparins crossover in percutaneous coronary interventions: a real issue with 
      increasing rate of transradial procedures?
PG  - 507-11
LID - 10.2459/JCM.0000000000000201 [doi]
AB  - AIMS: Current guidelines give a class III recommendation to the intraprocedural 
      use of unfractionated heparin (UFH) in patients pretreated with enoxaparin. The 
      aim of our study was to evaluate bleeding complications in patients who underwent 
      percutaneous coronary interventions (PCIs) performed using intraprocedural 
      crossover of heparin therapy. METHODS: We retrospectively evaluated all PCIs 
      performed at two Italian hospitals since January 2011 to December 2013. After a 
      propensity-matched analysis, patients were divided into two groups (with a ratio 
      1 : 2) according to intraprocedural crossover of heparins (from enoxaparin to 
      UFH) (Group 1) or intraprocedural UFH alone (Group 2). The primary end-point was 
      a haemoglobin drop of at least 3 g/dl within 48 h after the procedure. RESULTS: 
      During the 3 years analysed, 3224 patients underwent PCI, and after the 
      propensity analysis, 309 patients were considered eligible for our study: 104 
      patients in Group 1 (69 +/- 12 years, 78% men) and 205 patients in Group 2 (69 +/- 13 
      years, 80% men, P = NS). There were no significant differences between the two 
      groups for BMI, periprocedural use of antiplatelet therapy, baseline haemoglobin 
      haematocrit or platelets levels. The primary end-point did not differ between the 
      two groups (2.9% in Group 1 and 3.4% in Group 2, P = 0.550). Also, nadir of 
      haematocrit or haemoglobin levels did not differ between the two groups. Finally, 
      in hospital, major adverse cardio-cerebrovascular events did not differ between 
      the two groups (1.9% in Group 1 and 3.9% in Group 2, P = 0.50). CONCLUSION: In 
      this retrospective analysis of a large PCI database, the 'heparins crossover' 
      during PCI was not associated with increased bleeding risk.
FAU - Sciahbasi, Alessandro
AU  - Sciahbasi A
AD  - aDepartment of Interventional Cardiology, Sandro Pertini Hospital, ASL RMB 
      bDepartment of Cardiology, University La Sapienza cEmergency Department, Sandro 
      Pertini Hospital, ASL RMB, Rome, Italy.
FAU - Rigattieri, Stefano
AU  - Rigattieri S
FAU - Calcagno, Simone
AU  - Calcagno S
FAU - Mancone, Massimo
AU  - Mancone M
FAU - Pendenza, Gianluca
AU  - Pendenza G
FAU - Cera, Maria
AU  - Cera M
FAU - Danza, Aurora Ilaria
AU  - Danza AI
FAU - Di Russo, Cristian
AU  - Di Russo C
FAU - Bruno, Pasqualina
AU  - Bruno P
FAU - Fedele, Silvio
AU  - Fedele S
FAU - Pugliese, Francesco Rocco
AU  - Pugliese FR
FAU - Sardella, Gennaro
AU  - Sardella G
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*adverse effects
MH  - Drug Substitution/methods
MH  - Enoxaparin/administration & dosage
MH  - Female
MH  - Heparin/*adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Perioperative Care/*methods
MH  - Postoperative Hemorrhage/*etiology
MH  - Propensity Score
MH  - Retrospective Studies
EDAT- 2014/09/16 06:00
MHDA- 2016/02/18 06:00
CRDT- 2014/09/16 06:00
PHST- 2014/09/16 06:00 [entrez]
PHST- 2014/09/16 06:00 [pubmed]
PHST- 2016/02/18 06:00 [medline]
AID - 10.2459/JCM.0000000000000201 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):507-11. doi: 
      10.2459/JCM.0000000000000201.